Research programme: liver X receptor modulators - Bristol-Myers Squibb/Exelixis

Drug Profile

Research programme: liver X receptor modulators - Bristol-Myers Squibb/Exelixis

Alternative Names: EXEL 2255; LXR modulators

Latest Information Update: 20 Oct 2015

Price : $50

At a glance

  • Originator Exelixis
  • Developer Bristol-Myers Squibb; Exelixis
  • Class Small molecules
  • Mechanism of Action Liver X receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Atherosclerosis; Hypercholesterolaemia

Most Recent Events

  • 13 Oct 2010 Bristol-Myers Squibb and Exelixis make undisclosed minor amendments to their LXR agreement
  • 10 Nov 2008 Exelixis and Bristol-Myers Squibb extend their research collaboration until January 2010
  • 29 Nov 2007 An IND (or equivalent) has been accepted for a lead compound from this programme
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top